Diabetes was Accendra Health’s largest product and service line in fiscal 2025, bringing in $783.37M of $2.76B (28%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Diabetes | $723.32M | $777.48M | $783.37M |
| Sleep Therapy | $669.78M | $702.95M | $740.05M |
| Home Respiratory Therapy | $457.68M | $435.95M | $433.05M |
| Other | $254.97M | $268.27M | $288.19M |
| Ostomy | $177.89M | $195.92M | $212.84M |
| Wound Care | $170.95M | $192.41M | $188.51M |
| Urology | $97.99M | $107.12M | $116.02M |
| Total | $2.55B | $2.68B | $2.76B |
Accendra Health brought in $2.76B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 3.1% from $2.68B in fiscal 2024. Diabetes was the largest at $783.37M (28.4%), ahead of Sleep Therapy at $740.05M (26.8%) and Home Respiratory Therapy at $433.05M (15.7%). The other four lines brought in $805.56M combined.
Compared with fiscal 2024, Ostomy grew fastest, up 8.6% to $212.84M, while Wound Care fell the most, down 2.0% to $188.51M. From fiscal 2023 to 2025, combined revenue from these lines grew from $2.55B to $2.76B, a compound annual growth rate of 4.0%. Diabetes' share held steady at about 28.4%.
Commercial Payors was Accendra Health’s largest revenue line in fiscal 2025, bringing in $2.23B of $2.76B (81%).
| Customer | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Commercial Payors | $2.05B | $2.18B | $2.23B |
| Medicare | $463.47M | $461.97M | $497.80M |
| Medicaid | $38.39M | $40.18M | $38.46M |
| Total | $2.55B | $2.68B | $2.76B |
Accendra Health brought in $2.76B from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 3.1% from $2.68B in fiscal 2024. Commercial Payors was the largest at $2.23B (80.6%), ahead of Medicare at $497.80M (18.0%) and Medicaid at $38.46M (1.4%).
Compared with fiscal 2024, Medicare grew 7.8% to $497.80M and Commercial Payors grew 2.2% to $2.23B. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $2.55B to $2.76B, a compound annual growth rate of 4.0%. Commercial Payors' share held steady at about 80.6%.
Guarantor Subsidiaries was Accendra Health’s largest revenue line in fiscal 2017, bringing in $8.58B of $9.50B (90%).
| Consolidated Entities | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|
| Guarantor Subsidiaries | $9.18B | $9.19B | $8.58B |
| Non-Guarantor Subsidiaries | $751.44M | $697.56M | $915.35M |
| Total | $9.93B | $9.89B | $9.50B |
Accendra Health brought in $9.50B from its two revenue lines in fiscal 2017, the year ended December 31, 2017. That was down 3.9% from $9.89B in fiscal 2016. Guarantor Subsidiaries was the largest at $8.58B (90.4%), ahead of Non-Guarantor Subsidiaries at $915.35M (9.6%).
Compared with fiscal 2016, Non-Guarantor Subsidiaries grew 31.2% to $915.35M, while Guarantor Subsidiaries fell 6.6% to $8.58B. From fiscal 2015 to 2017, combined revenue from these revenue lines fell from $9.93B to $9.50B, a compound annual decline of 2.2%. Guarantor Subsidiaries' share of the total fell from 92.4% to 90.4%.
Accendra Health (ACH) reports its revenue by product and service, by customer and by consolidated entities. In fiscal 2025, Diabetes was its largest product and service line, bringing in $783.37M (28.4% of the total), followed by Sleep Therapy at $740.05M (26.8%).
Diabetes was Accendra Health's largest product and service line in fiscal 2025, bringing in $783.37M, or 28.4% of the $2.76B total across its seven product and service lines.
Commercial Payors was Accendra Health's largest revenue line in fiscal 2025, bringing in $2.23B, or 80.6% of the $2.76B total across its three revenue lines.
Among Accendra Health's product and service lines that make up at least 2% of revenue, Ostomy grew fastest in fiscal 2025, up 8.6% from $195.92M to $212.84M.
Every figure comes from Accendra Health's annual financial filings, as reported. Each line keeps the name Accendra Health gives it, and years follow its fiscal calendar.
Accendra Health's revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.